相关实验视频

Updated: Jan 13, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

在患有晚期恶性黑色素瘤的患者中,GRIm评分和对尼沃卢马布单一治疗的反应之间的关联

Sila Oksuz¹, Oguzcan Kinikoglu², Ugur Ozkerim²

¹Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, 34865, Istanbul, Turkey. sila.oksuz@gmail.com.

Journal of cancer research and clinical oncology

|January 8, 2026

概括

古斯塔夫·罗西免疫评分 (GRIm评分) 预测了在晚期黑色素瘤中对尼沃卢马布免疫疗法的反应. 较低的GRIm评分与明显更长的无进展和整体存活率有关,有助于患者分层.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
生物标志物发现发现

背景情况:

恶性黑色素瘤是一种具有高转移潜力的侵袭性皮肤癌.
免疫检查点抑制剂 (ICI),如尼沃卢马布,改善了晚期黑色素瘤的结果.
预测生物标志物对于分层患者和优化ICI治疗至关重要.

研究的目的:

评估古斯塔夫·鲁西免疫评分 (GRIm评分) 作为预后工具,用于预测第四阶段恶性黑色素瘤中对尼沃卢马布单一治疗的反应.
评估GRIm评分和临床结果之间的关联,包括无进展生存 (PFS) 和整体生存 (OS).

主要方法:

对40名IV期恶性黑色素瘤患者的回顾性分析,这些患者接受了尼沃卢马布治疗 (2020-2024年).
基于乳酸脱酶 (LDH),中性粒细胞与淋巴细胞比率 (NLR) 和白蛋白水平计算GRIm评分.
将患者分为低风险 (得分0 - 1) 和高风险 (得分2 - 3) 组.

主要成果:

低GRIm评分的患者的PFS中位数显著更长 (21.4个月与6.3个月,p=0.003) 和OS (26.5个月与7.2个月,p<0.001).
多变量分析确定GRIm评分作为一个独立的预后因素 (HR:1.593,p=0.004).
与GRIm评分的各个组成部分相比,GRIm评分显示出优越的预测能力.

结论:

这项研究首次验证了用nivolumab治疗恶性黑色素瘤患者的GRIm评分.
GRIm评分是免疫疗法试验中患者选择和改进治疗决策的宝贵生物标志物.
需要在更大,多中心的队列中进行进一步的验证,以证实这些发现.

关键词:

古斯塔夫·罗西的免疫评分 (GRIm评分)免疫疗法生物标志物恶性黑色素瘤是一种恶性黑色素瘤.尼沃卢马布的使用情况

更多相关视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...